Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof
US11975066B2 · kind B2 · utility
0Cited by
13References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 30, 2021 |
| Grant date | May 7, 2024 |
| Priority date | — |
| Expiry date | Jun 30, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/20034
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are human polyclonal immunoglobulin products for use in treating or preventing coronavirus disease. Further provided are methods for making such compositions in a transgenic ungulate, e.g. using a transchromosomic bovine (TcB) system.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.